Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey: In vitro/in vivo correlation and the role of aldehyde oxidase

Xenobiotica

Volumn 31, Issue 8-9, 2001, Pages 677-686

  Austin, N E ^a   Baldwin, S J ^a   Cutler, L ^a   Deeks, N ^a   Kelly, P J ^a   Nash, M ^a   Shardlow, C E ^a   Stemp, G ^a   Thewlis, K ^a   Ayrton, A ^a   Jeffrey, P ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE OXIDASE; AMIDE; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DRUG METABOLITE; ISOVANILLIN; N (3,4 DIMETHOXYPHENYL) N [3 [N [2 (3,4 DIMETHOXYPHENYL)ETHYL] N METHYLAMINO]PROPYL] 4 NITROBENZAMIDE; N (DIMETHOXYPHENYL) N [3 [[2 (3,4 DIMETHOXYPHENYL)ETHYL]METHYLAMINO]PROPYL] 4 NITROBENZAMIDE; N [4 [2 (6 CYANO 1,2,3,4 TETRAHYDRO 2 ISOQUINOLINYL)ETHYL]CYCLOHEXYL] 4 QUINOLINECARBOXAMIDE; N [4 [2 (6 CYANO 1,2,3,4 TETRAHYDROISOQUINOLIN 2 YL)ETHYL]CYCLOHEXYL] 2 OXO 1,2 DIHYDROQUINOLINE 4 CARBOXAMIDE; N [4 [2 (6 CYANO 1,2,3,4 TETRAHYDROISOQUINOLIN 2 YL)ETHYL]CYCLOHEXYL] 4 QUINOLININECARBOXAMIDE; QUINOLINE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SB 277011 A; SB 279832; SB 369912; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CORRELATION FUNCTION; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG OXIDATION; DRUG SELECTIVITY; FIRST PASS EFFECT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER HOMOGENATE; LIVER MICROSOME; MALE; METABOLIC INHIBITION; MONKEY; NONHUMAN; RAT; STANDARD;

ALDEHYDE OXIDASE; ALDEHYDE OXIDOREDUCTASES; ANIMALS; BIOLOGICAL AVAILABILITY; DOGS; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; LIVER; MACACA FASCICULARIS; MALE; MICROSOMES, LIVER; NADP; NITRILES; QUINOLINES; RATS; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SPECIES SPECIFICITY; TETRAHYDROISOQUINOLINES;

EID: 17944369889     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250110056531     Document Type: Article

References (14)

1. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone
2. Molybdenum hydroxylases as drug-metabolizing enzymes
3. Molybdenum hydroxylases: Biological distribution and substrate-inhibitor specificity
4. Species variation in hepatic aldehyde oxidase activity
5. Oxidation of carbor via molybdenum hydroxylases
6. 1-Substituted phthalazines as probes of the substrate-binding site of mammalian molybdenum hydroxylases
7. Models of drug absorption in situ and in conscious animals
8. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data
9. A comparison of the distribution and electron acceptor specificities of xanthine oxidase and aldehyde oxidase
10. Pharmacological actions of a novel, high-affinity, and selective human dopamine D3 receptor antagonist, SB-277011-A
11. Measurement of protein using bicinchoninic acid
12. 1-methylnicotinamide and pyridoxal
13. Purification and characterization of hepatic aldehyde oxidase in male and female mice